Get the Stockscreener App
201.04
0.56%
-1.14
After Hours:
201.04
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Quest Diagnostics Inc stock is traded at $201.04, with a volume of 1.02M.
It is down -0.56% in the last 24 hours and up +7.73% over the past month.
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
See More
Previous Close:
$202.18
Open:
$203.03
24h Volume:
1.02M
Relative Volume:
1.14
Market Cap:
$22.25B
Revenue:
$11.28B
Net Income/Loss:
$1.07B
P/E Ratio:
22.18
EPS:
9.0657
Net Cash Flow:
$1.33B
1W Performance:
-1.71%
1M Performance:
+7.73%
6M Performance:
+12.53%
1Y Performance:
+10.42%
1-Day Range:
$199.66
$204.70
1-Week Range:
$199.66
$207.50
52-Week Range:
$164.65
$213.50
Quest Diagnostics Inc Stock (DGX) Company Profile
Name
Quest Diagnostics Inc
Sector
Industry
Phone
(973) 520-2700
Address
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
201.04 | 22.38B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
472.63 | 176.04B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
181.35 | 128.18B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
573.00 | 44.96B | 4.45B | 1.10B | 1.06B | 13.59 |
A
Agilent Technologies Inc
|
128.34 | 36.88B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
360.54 | 35.13B | 3.77B | 449.25M | 240.68M | 7.8556 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-25-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-02-25 | Initiated | Redburn Atlantic | Buy |
| Mar-04-25 | Downgrade | Citigroup | Buy → Neutral |
| Jan-06-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-17-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | Jefferies | Buy |
| Oct-23-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-28-24 | Resumed | Evercore ISI | In-line |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Feb-07-24 | Upgrade | Jefferies | Hold → Buy |
| Jan-03-24 | Initiated | Barclays | Equal Weight |
| Dec-12-23 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-29-23 | Initiated | Piper Sandler | Neutral |
| May-02-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-03-23 | Upgrade | Citigroup | Sell → Neutral |
| Jan-23-23 | Initiated | Evercore ISI | In-line |
| Nov-17-22 | Downgrade | Citigroup | Neutral → Sell |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-04-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-23-22 | Downgrade | UBS | Buy → Neutral |
| Feb-02-22 | Downgrade | Jefferies | Buy → Hold |
| Jan-28-22 | Downgrade | Deutsche Bank | Buy → Hold |
| May-04-21 | Upgrade | UBS | Neutral → Buy |
| Mar-12-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-21-20 | Upgrade | Argus | Hold → Buy |
| Jul-29-20 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jul-14-20 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-09-20 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Jun-02-20 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-28-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-27-20 | Upgrade | Citigroup | Neutral → Buy |
| Apr-27-20 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Mar-27-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Jul-15-19 | Downgrade | Goldman | Neutral → Sell |
| Apr-02-19 | Upgrade | Jefferies | Hold → Buy |
| Mar-18-19 | Resumed | Credit Suisse | Neutral |
| Jan-31-19 | Downgrade | Argus | Buy → Hold |
| Jan-17-19 | Initiated | UBS | Neutral |
| Jan-03-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Dec-03-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-30-18 | Downgrade | Goldman | Buy → Neutral |
View All
Quest Diagnostics Inc Stock (DGX) Latest News
Health Coalition Issues Open Letter to Health Minister to Stop Transfer of Lab Testing by Quest/Lifelabs to U.S. - GlobeNewswire Inc.
Quest Diagnostics Stock (US74834L1008): Analyst Actions Shape Monday Focus After Quiet Newsflow - AD HOC NEWS
Quest Diagnostics Stock (US74834L1008): Stock in focus after calm trading and no fresh catalyst - AD HOC NEWS
Quest Diagnostics Stock (US74834L1008): Valuation in focus after a quiet week - AD HOC NEWS
Quest Diagnostics Incorporated (DGX) stock price, news, quote and history - Yahoo Finance UK
Quest Diagnostics Inc (NYSE:DGX): A Top Dividend Stock with Sustainable Income and Growth Potential - ChartMill
Quest Diagnostics Reports Second Quarter 2024 Financial Results; Raises Guidance for Full Year 2024 - GuruFocus
Zacks Industry Outlook Highlights Quest Diagnostics, DaVita, LifeStance Health and Aveanna Healthcare - Yahoo Finance
TD Asset Management Inc Sells 65,893 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score o - GuruFocus
Quest Diagnostics Inc (DGX) Shares Surge 3.7% -- What GF Score of 83 Tells Investors - GuruFocus
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics stock: Analyst estimates & ratings - MSN
4 Outpatient Home Health Stocks Benefiting From Industry Trends - TradingView
Fox Run Management L.L.C. Makes New Investment in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated $DGX Shares Purchased by Cibc World Market Inc. - MarketBeat
Quest Diagnostics Inc. stock underperforms Monday when compared to competitors - MarketWatch
[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity - Stock Titan
Fjarde AP Fonden Fourth Swedish National Pension Fund Acquires 7,700 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Bank of New York Mellon Corp Has $116.39 Million Stock Position in Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Incorporated (NYSE:DGX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
[144] QUEST DIAGNOSTICS INC SEC Filing - Stock Titan
How The Quest Diagnostics (DGX) Investment Story Is Evolving Without New Analyst Price Target Changes - Yahoo Finance
BNP Paribas Financial Markets Purchases 6,487 Shares of Quest Diagnostics Incorporated $DGX - MarketBeat
Quest Diagnostics Insider Sold Shares Worth $1,941,400, According to a Recent SEC Filing - marketscreener.com
Insider Sell: J. Davis Sells 10,000 Shares of Quest Diagnostics Inc (DGX) - GuruFocus
Quest Diagnostics CEO sells $1.94 million in company stock - Investing.com UK
Quest Diagnostics CEO sells $1.94 million in company stock By Investing.com - Investing.com Australia
Quest Diagnostics (DGX) CEO sells 10,000 shares in Rule 10b5-1 trade - Stock Titan
Affiliate sale notice — DGX (DGX) to sell 10,000 shares - Stock Titan
DGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Wall Street Zen Downgrades Quest Diagnostics (NYSE:DGX) to Hold - MarketBeat
Quest Diagnostics (DGX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock - Yahoo Finance
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Are Medical Stocks Lagging Quest Diagnostics (DGX) This Year? - Yahoo Finance
Quest Diagnostics Stock: Analyst Estimates & Ratings - Yahoo Finance
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting - Investing.com India
Quest Diagnostics 8-K SEC Filing May 2026: Shareholder Vote Results and Company Information - Minichart
Quest Diagnostics (DGX) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Quest Diagnostics shareholders elect directors and approve auditor at annual meeting By Investing.com - Investing.com South Africa
Quest Diagnostics (DGX) director granted 1,142 restricted stock units in Form 4 filing - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 RSUs - Stock Titan
Quest Diagnostics (DGX) director receives 1,142-share restricted stock unit grant - Stock Titan
Quest Diagnostics (DGX) director gets 1,142-share restricted stock unit award - Stock Titan
Director Tracey Doi of Quest Diagnostics (DGX) receives 1,142-share equity award - Stock Titan
Director at Quest Diagnostics (DGX) awarded 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (NYSE: DGX) receives 1,142 stock units - Stock Titan
Quest Diagnostics (DGX) director receives 1,142 restricted stock units - Stock Titan
Director at Quest Diagnostics (DGX) receives 1,142 share units - Stock Titan
Quest Diagnostics Inc Stock (DGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.25%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):